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Patients suffering from diabetic nephropathy, resulting in end-stage renal failure, are 
increasing in number. Pathophysiology of diabetic nephropathy remains to be fully 
investigated. In clinical settings, the presence of albuminuria/overt proteinuria and low 
glomerular filtration rate may predict poor renal prognosis, however, the prognosis of 
normoalbuminuric renal insufficient diabetic patients remains contravertial. In addition 
to the measurement of urinary albumin excretion, biomarker studies to detect diabetic 
nephropathy in the earlier stage more specifically have been investigated worldwide.   
A growing body of evidence reveals that remission and/or regression of diabetic 
nephropathy has been noted, which may be an indicator for cardiovascular and renal 
risk reduction.  Deeper insights into pathological characteristics as well as clinical 







 Based on the annual report of the Japanese Society for Dialysis Therapy (JSDT), 
diabetic nephropathy is a leading cause of end-stage renal failure in Japan (1).  The 
number of dialysis patients increased to 290, 675 at the end of 2009.  According to the 
annual report of JSDT, diabetic nephropathy has been a leading primary disease of new 
patients started on dialysis since 1998 (1).  The number of patients with diabetic 
nephropathy increased to 44.5% of new patients started on dialysis. In addition, 
cardiovascular diseases and death in patients with diabetes as underling renal disease 
before and after dialysis increase (2-3).  Therefore, the prevention and halting the 
progression of diabetic nephropathy is of importance to prolong the life survival. 
 
Characteristic pathologic changes of diabetic nephropathy are accumulation of 
extracellular matrix (ECM) and the infiltration of inflammatory cells in glomeruli and 
tubulointerstitial regions (4-5).  These pathologic abnormalities are implicated to be 
induced by the alterations of ECM production or degradation (6).   Generally speaking, 
the occurrence of albuminuria is a reflection of the increase in matrix deposition, 
leading to the glomerular and tubulointerstitial lesions.  Diabetic nephropathy is a 
clinical entity in which the presence of persistent albuminuria and decline in renal 
function as glomerular filtration rate (GFR) are the major characteristic findings, 
closely associated with end-stage renal diseases, enhanced cardiovascular morbidity and 
eventual mortality (7). The incidence of albuminuria, contributing to the diagnosis of 
the presence of diabetic nephropathy at present, is well correlated with decrease in GFR 
and the incidence of cardiovascular diseases as well.   
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Here, we focus on the clinical impact of albuminuria along with GFR levels on the 
progression of diabetic nephropathy and the incidence of cardiovascular diseases, 
closely related to the mortality in patients with diabetic nephropathy in this manuscript.  
 
Albuminuria as the diagnosis of diabetic nephropathy 
The definite diagnosis of diabetic nephropathy is based on the pathological findings, 
such as the presence of diffuse mesangial lesions and nodular lesions.  However, renal 
biopsy is not performed to all patients with diabetic nephropathy.  In clinical settings, 
the presence of persistent proteinuria as well as other complications, such as diabetic 
retinopathy, and renal dysfunction are of importance for the diagnosis of diabetic 
nephropathy.  However, the earlier detection of the presence of diabetic nephropathy is 
clinically required for the better prognosis.  To detect earlier diabetic nephropathy, the 
measurement of urinary excretion of albumin is essential at present.  The increased 
excretion of albumin (albuminuria) is implicated to be an early diagnostic tool for 
diabetic nephropathy.  In this aspect, Mogensen et al. proposed a classification of 
diabetic nephropathy in patients with type 1 diabetes based on increased urinary 
albumin excretion, once diabetic nephropathy was diagnosed (8).  Diabetic nephropathy 
is also staged in Japan (9, 10) and described by Yokoyama et al. as follows (11): Stage 
I: urinary albumin-to-creatinine ratio (ACR) <30mg/g creatinine; stage II: ACR≧30 
and <300mg/g creatinine (i.e., albuminuria); stage III: ACR≧300mg/g creatinine 
and/or persistent proteinuria with serum concentration of creatinine <2mg/dl; stage IV: 
serum concentration of creatinine ≧2mg/dl with protenuria; and stage V: being treated 
with dialysis. The Japan Diabetes Clinical Data Management Study Group (JDDM) 
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reported that the prevalence of albuminuria as Stage II in Japanese type 2 diabetic 
patients was 32%, which is almost similar to 39% observed in the DEMAND study 
(12).  These results suggest that albuminuria is common and that 76% of patients with 
diabetic nephropathy are categorized as Stage II, as evidenced by the presence of 
albuminuria.  Further, 58% of patients enrolled were staged as Stage I, 7% as Stage III, 
2.6% as Stage IV and 0.4% as Stage V (11).  A very recent study from the Japan 
Diabetes Complications Study (JDCS) revealed that the annual transition rate to 
proteinuria (ACR≧300mg/g creatinine) was 0.67% and that this was substantially 
higher for the low-albuminuric group defined as a urinary ACR of 30 to 150 mg/g 
creatinine than for the normoalbuminuric group defined as a urinary ACR of <30 mg/g 
creatinine (13).  In this sense, UKPDS 64 reported that the progression to 
albuminuria occurred at 2.0% per year, from albuminuria to macroalbuminuria 
at 2.8% per year (14).   However, about 40% of diabetic patients had no urinary 
albumin excretion measurements regardless of recommendation in JDDM cohort (11).  
Therefore, the measurement of urinary albumin excretion is required for the earlier 
detection of diabetic nephropathy in Japan.   
 
Biomarkers for diabetic nephropathy and disease progression 
Further studies to detect diabetic nephropathy in the earlier stage more specifically in 
addition to urinary albumin excretion are needed.  In this sense, biomarker studies to 
identify the presence and predict the progression of diabetic nephropathy have been 
investigated worldwide (15).  Recently, Kamijo-Ikemori et al. reported that urinary 
levels of liver-type fatty acid-binding protein (L-FABP) accurately reflected the 
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severity of diabetic nephropathy in type 2 diabetes (16).  Importantly, urinary L-FABP 
levels were high in the patients with normoalbuminuria, suggesting its usefulness to 
detect earlier nephropathy in these patients.  Further, the increase in urinary Smad1, a 
key transcriptional factor for mesangial matrix expansion in diabetic nephropathy, in 
early stage was correlated with later development of glomerulosclerosis in experimental 
rodent models (17).   Regarding renal function, serum cystatin C was reported to be a 
good marker for detecting nephropathy (18). Notably, cases of early renal dysfunction, 
defined by loss in cystatin C GFR exceeding -3.3%/year, occurred in 9% of the 
normoalbuminuria group and 31% of the albuminuria group (19).   
 
Prevalence of albuminuria and low GFR in type 2 diabetic patients in Japan  
As previously described, diabetic nephropathy is diagnosed by the detection of 
albuminuria.  Recently, Kidney Disease Improving Global Outcomes (KDIGO) 
reported the definition, classification and prognosis of chronic kidney disease       based 
both on estimated GFR and urinary levels of albumin excretion (20).  In this sense, 
there are diabetic patients with decrease in GFR and normoalbuminuria. Is diabetic 
nephropathy observed in such patients? In fact, the percentage of diabetic patients with 
normoalbuminuria and low estimated GFR is supposed to be relatively common.  
Importantly, Yokoyama et al. described that the proportion of subjects with low 
estimated GFR (<60ml/min/1.73m2) and normoalbuminuria was 11.4% of type 2 
diabetic patients examined (262/2298) (21).  In this manuscript, 63.4% of these 262 
patients had neither diabetic retinopathy nor neuropathy.  Of note, these patients were 
older and included a higher proportion of women and patients with hypertension, 
hyperlipidemia and cardiovascular disease, and fewer smokers compared with those 
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with normoalbuminuria and preserved GFR.  In contrast, the proportion of type 2 
diabetic patients with preserved GFR, having albuminuria or overt proteinuria was 27% 
(755/2791).  Most importantly, the lack of histological proven diabetic nephropathy 
should be discussed.  In type 1 diabetes patients with normoalbuminuria and low GFR, 
renal biopsy specimens revealed more advanced diabetic glomerular lesions. Of note, 
the finding of reduced GFR was much more common among female patients, 
particularly if retinopathy and/or hypertension were also present (22).  Deep insight into 
prevalence and prognosis of these patients with proven pathological characteristics and 
grading would be required to understand the pathophysiology of diabetic nephropathy 
more in depth together with future perspectives. 
 
Clinical impacts of albuminuria and GFR on the prognosis in diabetic 
patients  
Obviously, the diabetic patients together with albuminuria/overt proteinuria and low 
GFR had the risk for adverse outcomes, including cardiovascular events, cardiovascular 
death, and renal events as reported by the Action in Diabetes and Vascular disease: 
preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study (23) (Figure 
1).  Do normoalbuminuric renal insufficient diabetic patients have poor prognosis?  
Rigalleau et al. reported that risk for renal progression and death in these patients with 
type 1 or type 2 diabetes is lower (24).  Concomitantly, in type 2 diabetic patients, the 
Casale Monferrato study revealed that macroalbuminuira was the main predictor of 
mortality, independently of both estimated GFR and cardiovascular risk factors, 
whereas estimated GFR provided no further information for all-cause mortality and 
cardiovascular mortality in normoalbuminuric patients (25). Supporting this notion, 
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regarding renal end points, there was also a progressive increase in risk associations 
with declined renal function, which was mainly observed in the albuminuric group in 
Chinese type 2 diabetic patients (26).  Interestingly, reduced estimated GFR were at 
high risk of developing cardiovascular end points (cardiovascular death, new 
admissions due to angina, myocardial infarction, stroke, revasculization or heart failure) 
and all-cause mortality independent of albuminuria (26).  On the contrary, as previously 
described, in ADVANCE study, patients with normoalbuminuria and estimated 
GFR<60ml/min per 1.73 m2 had a 3.95-fold higher risk for renal event, a 1.33-fold 
higher risk for cardiovascular events and a 1.85-fold higher risk for cardiovascular 
death (23) (Figure 1). Moreover, Vlek et al. reported that estimated GFR<60 
ml/min/1.73 m2 without albuminuria mainly influenced the risk of vascular events 
(hazard ratio 1.50; 1.05-2.15) (27).  Recently, the Fenofibrate Intervention and 
Event Lowering in Diabetes (FIELD) study revealed that normoalbuminuric 
patients with eGFR 30-59 ml/min per 1.73 m2 had a higher risk of a cardiovascular 
events, cardiovascular death, non-coronary heart disease deaths, death from any 
cause than normoalbuminuric patients with eGFR ≧60 ml/min per 1.73 m2 (28).   
Interestingly, high normal levels of albuminuria (>5g/min) predict the 
development of micro-and macroalbuminuria and increased mortality in Brazilian 
type 2 diabetic patients (29). Furthermore, in Japanese patients with type 1 and 
type 2 diabetes, even within the normal range (<30 mg/g), albumin-to-creatinine 
ratio ≧10mg/g in women and ≧5mg/g in men was associated with a significantly 
greater rate of decline in eGFR relative to subjects with  albumin-to-creatinine 
ratio <5 mg/g (30). It is of interest that the risk of cardiovascular events in 
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individuals with diabetes increases with the albumin-to-creatinine ratio, starting 
well below the microalbumin cutoff (31).  Taken together, evaluation of clinical 
impacts of albuminuria along with the evaluation of GFR on the prognosis in diabetic 
patients is required. 
 
Remission/regression of albuminuria in patients with diabetic 
nephropathy 
Of note, Fioretto et al. reported that pancreas transplantation reversed the lesions of 
diabetic nephropathy in patients with type 1 diabetes mellitus, but that reversal required 
more than five years of normoglycemia (32).  Thereafter, a growing body of evidence 
reveals that remission and/or regression of diabetic nephropathy has been noted these 
days, especially in patients treated with renin-angiotensin system blockade drugs. The 
issues are lack of data on pathological findings in these patients.  In clinical settings in 
patients with type 1 diabetes mellitus, Perkins et al. described that regression of 
albuminuria was frequent, with a six-year cumulative incidence of 58% (33).  In this 
context, definition of regression of microalbuminuria is a 50 percent reduction in 
albumin excretion from one two-year period to the next.  In addition, Hovind et al. at 
Steno Diabetes Center reported that the total number of patients who obtained remission 
was 92 (31%), with a duration of remission of 3.4 years, and regression 67 (22%) in 301 
consecutive type 1 diabetic patients with diabetic nephropathy (34).   Remission was 
defined as albuminuria <200 microg/min sustained for at least one year and a decrease 
of at least 30% from preremission levels, and regression as rate of decline in GFR equal 
to the natural aging process: < or =1 ml/min/year during the investigation period in this 
report.  Moreover, remission of nephrotic-range albuminuria in type 1 diabetic patients 
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was also reported at Steno Diabetes Center (35).  In this report, remission was induced 
in 28 of 126 (22%) patients; 21 were predominantly treated with angiotensin converting 
enzyme (ACE) inhibitors, 7 with non-ACE inhibitor medications.  Remission lasted 3.6 
years.  In particular, more women (37%) than men (16%) obtained remission.  In 
addition to type 1 diabetic patients, recent studies reveal that remission is induced in 
type 2 diabetic patients.  Araki et al. reported that reduction of urinary albumin 
excretion rate was frequent, with a 6-year cumulative incidence of 51% for remission, 
defined as shift to normoalbuminuria, and 54% for regression, defined as a 50% 
reduction in urinary albumin excretion rate (36).  Interestingly, in this particular study, 
the frequency of progression to overt proteinuria was 28% and albuminuria of short 
duration, the use of renin-angiotensin system-blocking drugs, and lower titers for 
HbA1c and systolic blood pressure were independently associated with remission or 
regression.  More recently, JDCS revealed that return from low-microalbuminuria to 
normoalbuminuria was observed in 137 out of 452 patients (30.3%) (13).  
Further, clinical impact of remission/regression on renal outcome and cardiovascular 
events remains fully investigated.  Importantly, Araki et al. have reported that a 
reduction of albuminuria in patients with type 2 diabetes is an indicator for 
cardiovascular and renal risk reduction (37).  In this study, the cumulative incidence of 
death from and hospitalization for renal and cardiovascular events was significantly 
lower in patients with a 50% reduction.  Collectively, remission/regression in patients 
with diabetic nephropathy is relatively frequent and insights into pathological 
characteristics as well as clinical impacts on renal and cardiovascular outcomes when 
remission/regression is induced would be needed. 
 
 11
Hematuria in diabetic nephropathy 
Incidence of hematuria, other major characteristics finding than albuminuria/overt 
proteinuria, was reported in 14 out of 34 Japanese patients with biopsy-proven diabetic 
nephropathy (38).  Patients having hematuria had a significantly lower renal function 
and the prevalence of nephrotic syndrome and retinopathy was significantly higher than 
that in the patients without hematuria. Interestingly, based on a logistic regression 
analysis, the presence of nephrotic syndrome and known duration of diabetes were 
identified to be significant predictors for hematuria with diabetic nephropathy.   
 
Concluding remarks and future directions 
A deep insight of the onset and progression of albuminuria along with GFR may 
provide a key for the pathogenesis of progressive kidney complications and associated 
cardiovascular diseases.  Further studies for clinical characteristics and pathological 
findings of kidney involvement in patients with diabetes would be required for a better 
understanding and the therapeutic benefit for diabetic nephropathy. 
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Combined effects of albuminuria and eGFR levels at baseline on the risk for adverse 
outcomes.  The estimates are adjusted for baseline covariates, including age, gender, 
duration of diabetes, SBP, history of currently treated hypertension, history of 
macrovascular disease, HbA1c, LDL cholesterol, HDL cholesterol, log-transformed 
triglycerides, BMI, electrocardiogram abnormalities, current smoking, and current 
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